Quick filters
- European equity funds ride recent market rally Globe and Mail | Sunday May 19, 2013 7:00PM
- Assessing Your Asthma is Key to Taking Control PR Newswire | Monday May 13, 2013 3:00PM
- Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period Business Wire | Monday May 6, 2013 7:00AM
- Danish drug makers recuperating nicely Globe and Mail | Wednesday May 1, 2013 11:41AM
- Glaxo loses thirst for iconic beverage brands Globe and Mail | Wednesday April 24, 2013 2:51PM
- AstraZeneca outlook long on hope, short on details Globe and Mail | Thursday March 21, 2013 3:36PM
- Pared-down AstraZeneca to cut one in 10 jobs Globe and Mail | Thursday March 21, 2013 6:06AM
- AstraZeneca to Establish Strategic R&D Center in Gaithersburg, Md; Wilmington Remains North America Commercial Headquarters Business Wire | Monday March 18, 2013 9:05AM
- AstraZeneca Encourages Atherosclerosis Education among High Risk Patients during American Heart Month PR Newswire | Thursday February 14, 2013 9:00AM
- AstraZeneca Recognized as a Top Company for Female Executives Business Wire | Tuesday February 5, 2013 12:30PM
- A pain relief regimen for AstraZeneca Globe and Mail | Thursday January 31, 2013 1:20PM
- New AstraZeneca CEO plans to invest through tough year Globe and Mail | Thursday January 31, 2013 7:48AM
- AstraZeneca HealthCare Foundation: Connections for Cardiovascular HealthSM Accepting Grant Applications Business Wire | Wednesday January 9, 2013 9:38AM
- A trio of value stocks in the Buffett mould Globe and Mail | Monday December 17, 2012 7:40PM
- BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients Business Wire | Monday December 17, 2012 3:50PM
- CRESTOR® US Patent Upheld by Court of Appeals for the Federal Circuit Business Wire | Friday December 14, 2012 1:21PM
- AstraZeneca Updates US Label For FASLODEX® (fulvestrant) Injection Business Wire | Wednesday December 5, 2012 11:30AM
- Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared with 250 mg.1,2 Business Wire | Wednesday December 5, 2012 8:35AM
- AstraZeneca to Present Key New Data for Hormone Receptor-Positive Metastatic Breast Cancer at the 35th CTRC-AACR Annual San Antonio Breast Cancer Symposium Business Wire | Tuesday December 4, 2012 2:00PM
- AstraZeneca Makes Major Commitment to Help Patients with Acute Coronary Syndrome Have BRILINTA (ticagrelor) Available in Their Local Communities Business Wire | Tuesday December 4, 2012 9:30AM
Live Discussion of AZN on StockTwits